Gujarat Themis Biosyn Ltd - GUJ. THEMIS BIO. Share Price

Sector: Pharmaceuticals | ISIN: INE942C01029

Gujarat Themis Biosyn Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 5/8/2024 12:00:00 AM

    ₹ 409.55 -6.35 -1.53
  • Open
  • ₹ 410.3
  • Prev. Close
  • ₹ 415.9
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 414.9
  • Day's Low
  • ₹ 402
  • 52 Week's High
  • ₹ 435
  • 52 Week's Low
  • ₹ 145.8
  • Book Value
  • ₹ 24.502
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 2,975.11
  • P/E
  • 54.1
  • EPS
  • 7.57
  • Divi. Yield
  • 0.26

Gujarat Themis Biosyn Ltd Corporate Actions

10 Feb , 2024

12:00 AM

Dividend

Dividend amount: 0.75
Announcement date: 10 Feb , 2024

View Details

29 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

29 Jan , 2024

12:00 AM

25 Oct , 2023

12:00 AM

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 May , 2023

12:00 AM

13 May , 2023

12:00 AM

AGM

Announcement date: 13 May , 2023

View Details

13 May , 2023

12:00 AM

Dividend

Dividend amount: 1
Announcement date: 13 May , 2023

View Details

02 Aug , 2023

12:00 AM

02 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 May , 2023

12:00 AM

BookCloser

View Details

No Record Found


Gujarat Themis Biosyn Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Gujarat Themis Biosyn Ltd SHAREHOLDING SNAPSHOT
09 May , 2024 | 05:45 AM

PROMOTER - TOTAL70.86%

Indian: 70.86%

Foreign: 0%

NON-PROMOTER - TOTAL 29.14%

Institutions: 1.87%

Non-Institutions: 27.26%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Gujarat Themis Biosyn Ltd FINANCIALS

View Profit & Loss Graph

Gujarat Themis Biosyn Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Gujarat Themis Biosyn Ltd

  • Dinesh S Patel
  • Chairman & Non Executive Dir.
  • Sachin D Patel
  • Non Executive Director
  • VIJAY GOPI KISHAN AGARWAL
  • Independent Non Exe. Director
  • Kirandeep Madan
  • Independent Non Exe. Director
  • Vikram D Sanghvi
  • Independent Non Exe. Director
  • Siddharth Y Kusumgar
  • Independent Non Exe. Director

Summary

Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007.Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL.During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the... Read More


Reports by Gujarat Themis Biosyn Ltd


Reports by Gujarat Themis Biosyn Ltd

Company FAQ

No Record Found